To identify the predictor factors, such as prostate-specific Background: antigen (PSA), age, prostate volume (PV), and PSA density (PSAD) as indications to perform transrectal ultrasonography (TRUS)-guided prostate biopsy in reducing unnecessary biopsies and improving detection rate.
Introduction
Prostate cancer (PCa) is an important health issue worldwide because of its increasing incidence; it was reported that there are 1.1 million PCa patients worldwide in 2012 1 . The incidence of PCa among Indonesian men was estimated to be 14.8 per 100,000 population and the mortality rate was reported as high as 9.8 per 100,000 population in 2012 1 .
Transrectal ultrasonography (TRUS) guided biopsy plays an important role for PCa detection and has become a standard diagnostic method for PCa detection. It is recommended for men with elevated prostate specific antigen (PSA) levels or abnormal digital rectal examination (DRE). In Indonesia, 66.5% of PCa was diagnosed with TRUS-guided biopsy during 1994-2005 and 66.7% of them were found in advanced stage during this period 2, 3 . An appropriate and early detection are needed to detect PCa in its early stages for better treatment results, survival rates, and quality of life 4 .
The detection rate of prostate biopsy in several Asian countries varied between 14.6% and 26.5% in patients with PSA levels ranging from 2-20 ng/ml 5 . This widely used procedure for PCa remains controversial as it may lead to over-diagnosis (23%-42%) and over-treatment 5 . Both are related to unnecessary risk of urinary, sexual, and bowel dysfunction, which can affect patients' quality of life 4, 6 . Although TRUS-guided prostate biopsy is a safe procedure, there are still complications causing significant morbidity. The most common complications are mild hematuria (62%), rectal bleeding (2%), urinary tract infections (1.7%-11.3%), acute urinary retention (0.3%-2.6%), hematospermia (45.3%-50.4%), vasovagal response (2.8%), and hospitalization due to infection (1%-4.1%) 7,8 ). Systematic screening for prostate cancer by determining other factors besides PSA may assist prevention of this circumstance 5 .
The aim of this study was to identify the predictor factors such as PSA, age, prostate volume (PV), and PSA density (PSAD) as indications to perform TRUS guided prostate biopsy. Those variables are thought to be important predictors to reduce unnecessary biopsies and improve detection rate.
Methods

Data source
This retrospective study was approved by FKUI Research Ethical Committee before data collection began. We collected data pre-biopsy data, including age, PSA, prostate volume, and PSAD. These data were obtained from the medical records of patients that underwent prostate biopsy from January 2008 to December 2013 in Cipto Mangunkusumo Hospital, Jakarta, Indonesia. The inclusion criteria were patients with LUTS, PSA level >4 ng/ml, abnormal DRE, IPSS score >7, and age >45 years old, while the exclusion criteria were patients who underwent transperineal prostate biopsy or had been biopsied previously. The indications for prostate biopsy in our hospital were PSA level >4 ng/ml or abnormal DRE. All patients underwent 6-12-core biopsy using an 18-gauge needle with a springloaded biopsy gun (Bard Magnum). PV was calculated by measuring height (H), width (W), and length (L) of the prostate on TRUS and the formula would be: V= 0.52 x H x W x L. Collected data were further analyzed. Although this study was conducted in a single institution, we believe it is representative of Indonesian men because the samples are recruited from several provinces in Indonesia, since Cipto Mangunkusumo Hospital is a national referral hospital in Indonesia.
Statistical analysis
The study analysis was performed with SPSS version 20.0. We calculated the statistical analysis using Mann-Whitney test and unpaired t-test for the quantitative variables (age, PV, PSA and PSAD). In addition, Chi-square was used for statistical significance for qualitative variables. P <0.05 was considered as a significant result. Receiver operating characteristic (ROC) curve analysis was also conducted to determine the cut-off point and the optimum specificity and sensitivity for each variable.
Results
Baseline characteristics
A total of 1232 patients who underwent prostate biopsy were retrospectively analyzed. Among those patients, 413 patients had positive biopsy results (diagnosed with PCa) and 819 patients had negative biopsy result (diagnosed with benign prostate hyperplasia (BPH) or prostatitis). The characteristics of patients in this study can be viewed in Table 1 .
Comparison between biopsy groups
Compared to the negative biopsy group, the positive biopsy group had lower median PV, while serum PSA level and age in positive biopsy group was higher than negative biopsy group ( Table 1 ). The mean PSAD in positive biopsy result group was higher than negative biopsy results, except PSAD in patients with PSA <4 ng/ml (Table 1) .
Bivariate analysis using the Mann-Whitney U-test showed that age (p <0.001), PSA (p <0.001), PV (p <0.001), and PSAD in patients with PSA 4-10 ng/ml (p <0.001), 10-20 ng/ml (p <0.001), and >20 ng/ml (p <0.001) group had statistical significance differences. However, PSAD in patients with PSA <4 ng/ml (p=0.368) showed no statistically significant difference using unpaired t-test.
According to the age groups, we classified them into three groups based on previous study 9 . As shown in Table 2 , those aged >70 years (43.4%) had the highest detection rate. In addition, the positive biopsy rate in patients with PSA >20 ng/ml was 57.2 %. Prostate volume <60 ml had higher detection rate (41.8%) compared to PV >60 ml which only has 18.2% ( Table 2) .
ROC analysis
The ROC curve demonstrated that PSAD was the best predictor factor among those variables (age, PSA, and PV) in TRUSguided prostate biopsy ( Figure 1 and Table 3 ). The area under the curve (AUC) for PSAD (84.5%) and PSA (78.7%), while the AUC for PV and age were 62.4% and 61.2%, respectively. PSAD and PSA were thus considered better predictors for identifying PCa than PV and age. This study also conducted ROC curve analysis for PSAD in stratified PSA level ( Table 3 ).
The optimal cut-off point of PSAD in the PSA group of 4-10 ng/ml was 0.17 ng/ml and its sensitivity and specificity were 75% and 66.5%, respectively. The cut-off point of PSA level was 32.5 ng/ml, giving a sensitivity and specificity for PSA of 62.0% and 87.1%, respectively. Prostate volume and age had lower optimum sensitivity and specificity compared to PSAD and PSA. (Table 3 ) This study divided PSAD variables into four groups based on PSA level (Table 3) .
Discussion
Rashid et al. stated that TRUS-guided biopsy is recommended as the procedure of choice for early detection of PCa. Even though the elevation of PSA and the presence of an abnormal DRE are associated with PCa, those kind of examinations are not appropriate as a standard predictor 9 .
In our study, 33.5% of the 1,232 patients examined had prostate cancer based on the biopsy result of histopathology examination. The overall detection rate (33.5%) of PCa in this study was much lower than in Pakistan (50.3%) 10 . Na et al.
and Presti et al. also showed differences compared to earlier Chinese and American studies; they reported that the detection rates were 47% and 42%, respectively 11,12 .
The same results in positive biopsy rate are also found in other studies ( 11, 20 . In addition, the mean age of a group in Korea was found to be lower (63.8 years old) than that in the current study, but its result cannot be compared because the study use tPSA level less than 10 ng/ml 21 .
Age is one of many risk factors affecting PCa because the incidence of the disease increases along with aging. This study shows that patients with PSA level 4-10 ng/ml and 10-20 ng/ml had lower detection rate compared to those with PSA level below 4 ng/ml. Prakash et al. also generated similar results to those of our study, showing that PCa in patients with PSA level <4 ng/ml was could be detected more easily compared to patients with PSA levels of 4-10 ng/ml and 10-20 ng/ml, with the addition of DRE examination 13 . These results suggested that DRE may still have an important role in assisting or predicting PCa in suspicious patients 23 . Previous studies conducted in Taiwan and The Netherlands also revealed that DRE is an independent predictor of PCa 19,24 .
In this study, the lowest detection rate of PCa is in those with a PSA level of 4-10 ng/ml. Therefore, PSA alone is not an effective screening method to diagnose PCa. PSA level alone could cause the high rate of false positive or negative biopsy rate in patients that underwent TRUS-guided prostate biopsy. PSA is a protein produced by the prostatic epithelium. It is organspecific, but not cancer-specific. PSA can be manipulated by other disorders of the prostate, such as prostatitis, urinary retention, and BPH. Research into a large population regarding PSA screening in ERSPC revealed that PSA screening was able to reduce a number of 20% mortality in patients with PCa.
Another study reported that PSA had no benefit in reducing mortality in PCa. PSA alone is not optimal to determine the risk of PCa 11 . Other factors such as DRE, TRUS to asses PV, and PSAD must be considered when performing prostate biopsy 24 .
The role of PV as a predictor factor is still being debated. In this study, the mean PV in patients with PCa is much lower than in those with negative biopsy results. A previous study in Indonesia conducted by Ariani et al. produced the same result as our study 16 . The study revealed that the incidence of PCa increased with decreasing PV 16 This study revealed that PSAD had the best predictor in detecting PCa. A study from China showed a similar ROC cut-off 29 . This examination could be used to reduce unnecessary biopsy because the specificity of PSAD was much higher than specificity of PSA level 4 ng/ml (as indicated for prostate biopsy) in this study.
The limitation of our study is that the TRUS-guided biopsy is of limited value. It can only show small number of malignancies. The use of contrast agent combined with TRUS-guided prostate biopsy can increase the accuracy of prostate cancer diagnosis 29 . We also noticed that according to Prakash et al., the number of core biopsies have to be increased up to 16 cores in order to significantly increase the rate of prostate cancer detection 13 .
Another limitation of this study is that it is a retrospective study conducted in a single institution. In this study, PSA level was not defined adequately, therefore the cut-off point and mean variables were difficult to obtain. Although this study is conducted in a single institution, it can represent the races from Indonesian men because the samples are recruited from several provinces in Indonesia.
Conclusion
In conclusion, the overall detection rate of PCa by biopsy in our study is 33.5%, much lower than other countries in Asia. The incidence of PCa increased with higher PSA level, older age and lower PV. Utilization of PSAD 0.17 ng/ml/ml as a cut-off point in patients with PSA level between 4-10 ng/ml is recommended to improve PCa detection in Indonesian men. 
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